The insider sales are too small to be informative. Focus on the strong Q1 earnings and BRINSUPRI launch trajectory as the primary catalysts. Monitor for any larger insider sales in the coming weeks that could signal a change in sentiment.
INSM drugs
INSM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 4 $140.01entry
- T+1 · 7mo ago −0.41%α −1.20% · $139.44
- T+5 · 6mo ago −25.80%α −28.73% · $103.89
- T+20 · 6mo ago −24.27%α −29.91% · $106.03
- T+60 · 4mo ago −26.35%α −28.20% · $103.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Insmed's CEO and CMO sold a combined $1.27M in stock within a week of a strong Q1 2026 earnings beat (revenue up 230% YoY, EPS beat). The CMO's sale ($1.22M) is a cash-out following option exercises; the CEO's sale ($58K) is routine. At 0.005% of market cap, the total is trivial and likely liquidity-driven, not a bearish signal.
Key Financial Metrics
Key Facts
- CEO William Lewis sold 433 shares for ~$58K on May 4, 2026.
- CMO Martina Flammer sold 12,119 shares for ~$1.22M on May 11, 2026, following option exercises.
- Total cluster value of $1.27M represents ~0.005% of INSM's $25.1B market cap.
- Q1 2026 revenue of $306M (up 230% YoY) and EPS beat consensus; BRINSUPRI guidance reiterated at ≥$1B.
- All cross-filing context pairs are AMPLIFIERS, but the dollar amount is too small to warrant escalation.
Financial Impact
Total insider sales of $1.27M, negligible relative to $25.1B market cap.
Risk Factors
- Insider sales could accelerate if the stock continues to rally post-earnings.
- Any negative news on BRINSUPRI reimbursement or competition could reverse recent gains.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-INSM-1778705432876 |
Track record
24 reports on INSM
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +31.86% at T+60 after the Mar 30, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $110.00 Now $121.16 +10.15% settles Dec 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $110.00 Now $121.16 +10.15% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $111.59 Now $121.16 +8.58% settles Nov 27
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $94.04 Now $121.16 +28.84% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $95.67 Now $121.16 +26.64% settles Nov 17
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $103.83 to $112.58 Now $121.16 +16.69% ▲ +8.43% +10.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 4/10 Entry $125.08 to $120.00 Now $121.16 −3.13% ▼ −4.06% −4.19% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $126.33 to $129.41 Now $121.16 −4.09% ▲ +2.44% +4.19% vs SPY
- Aug 6, 202614w ago 8-K Bullish 8/10 Entry $132.55 to $126.68 Now $121.16 −8.59% ▼ −4.43% −5.03% vs SPY
- Jul 24, 202616w ago Institutional Cluster Neutral 4/10 Entry $106.92 to $125.77 Now $121.16 +13.32% ▲ +17.63% +14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers